NasdaqGM:GHRSPharmaceuticals
Assessing GH Research (GHRS) Valuation After FDA Lifts Clinical Hold On GH001 IND
GH Research (NasdaqGM:GHRS) is back in focus after the U.S. Food and Drug Administration lifted the clinical hold on its GH001 IND, clearing the way for U.S. enrollment in treatment-resistant depression trials.
See our latest analysis for GH Research.
The FDA decision appears to have been a key catalyst, with a 1 day share price return of 27.12% and a 7 day share price return of 41.34% lifting the stock to $17.95. At the same time, the 1 year total shareholder return of 99.89% and 3 year...